Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDFI mice
1997

Liposomal Mitoxantrone: Improved Delivery and Reduced Toxicity

Sample size: 10 publication Evidence: moderate

Author Information

Author(s): CW Chang, L Barber, C Ouyang, D Masin, MB Bally, TD Madden

Primary Institution: University of British Columbia

Hypothesis

Can mitoxantrone encapsulated in liposomes improve therapeutic efficacy and reduce toxicity compared to free drug?

Conclusion

Liposomal encapsulation of mitoxantrone significantly reduces its toxicity and allows for higher, more effective doses.

Supporting Evidence

  • Liposomal mitoxantrone showed over 90% retention in circulation one hour after administration.
  • Survival rates of 40% were observed in mice treated with liposomal mitoxantrone compared to no long-term survivors with free drug.
  • Liposomal formulations allowed for higher doses of mitoxantrone with reduced toxicity.

Takeaway

This study shows that putting a cancer drug called mitoxantrone inside tiny bubbles called liposomes helps it work better and makes it less harmful.

Methodology

The study involved administering free mitoxantrone and liposomal formulations to mice and comparing their plasma clearance and biodistribution.

Limitations

The study was conducted in mice, which may not fully represent human responses.

Participant Demographics

BDFI mice, 8-9 weeks old, weighing 18.0-23.0 g.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication